Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

CO-ZANSOR 300/12.5MG F.C. TABLETS - SFDA Drug Approval Details

Approvals/SFDA/CO-ZANSOR 300/12.5MG F.C. TABLETS

Authorized

GENERIC

CO-ZANSOR 300/12.5MG F.C. TABLETS

Unknown🇸🇦 Saudi Food and Drug Authority

Approval Date: N/A
Approval ID: 0605e57340f4ebaa
Company: Unknown
Type: Generic

Approval Details

Approval Id: 0605e57340f4ebaa
Drug Approval Sfda Name: CO-ZANSOR 300/12.5MG F.C. TABLETS
Trade Name: CO-ZANSOR 300/12.5MG F.C. TABLETS
Generic Name: IRBESARTAN,HYDROCHLOROTHIAZIDE
Register Number: 54-968-20
Register Year: 2020
Drug Type: Generic
Route Of Administration: Oral use
Package Type: Blister
Package Size: 28
Legal Status: Prescription
Authorization Status: Valid
Marketing Status: Marketed
Product Control: Uncontrolled
Storage Conditions: store below 30°c
Shelf Life: 24 Months
Distribution Site: Pharmacy
Description Code: 14000001324-312.5-100000073665
Price: 47.7

Active Ingredients

Authorized

Quick Info

Agency

SFDA

Country

🇸🇦

Approval ID

0605e57340f4ebaa

Type

Generic

Back to SFDA Approvals